Every material Form 8-K Bio-Techne filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bio-Techne reported results for the first quarter ended September 30, 2025, with net sales down 1% to $286.6 million, GAAP diluted EPS up to $0.24 from $0.21, and adjusted EPS flat at $0.42. The filing also shows the company declared an $0.08 per share dividend and that shareholders elected all nine director nominees and approved executive pay at the annual meeting. For shareholders, the key tension is a smaller revenue base alongside higher GAAP profit.
Net sales fell 1% to $286.6 million; organic revenue also decreased 1%.
GAAP diluted EPS was $0.24 versus $0.21; adjusted diluted EPS was $0.42 in both periods.
Completed the divestiture of the Exosome Diagnostics business, including the ExoDx Prostate test.
Declared a dividend of $0.08 per share, payable November 28, 2025, to holders of record on November 17, 2025.
Bio-Techne reported fourth-quarter fiscal 2025 net sales up 4% to $317.0 million and adjusted EPS of $0.53, versus $0.49 a year earlier. GAAP EPS was a loss of $0.11, compared with $0.25, after an $83.1 million impairment tied to the planned divestiture of its Exosome Diagnostics business. The company also declared a quarterly dividend of $0.08 per share.
Q4 net sales $317.0 million, up 4% reported and 3% organic; full-year net sales $1.2 billion, up 5%
Q4 GAAP EPS was ($0.11) versus $0.25; full-year GAAP EPS was $0.46 versus $1.05
Q4 adjusted EPS $0.53 versus $0.49; full-year adjusted EPS $1.92 versus $1.77
Exosome Diagnostics impairment of $83.1 million in the quarter; dividend of $0.08 per share payable August 29, 2025 to holders of record August 18, 2025
Bio-Techne reported fiscal third-quarter results for the period ended March 31, 2025, with net sales up 4% to $316.2 million and adjusted EPS up to $0.56 from $0.48. GAAP EPS fell to $0.14 from $0.31, as GAAP operating income dropped 42% to $38.7 million, which the company tied to a non-recurring arbitration award and $38.9 million in certain litigation charges. The company also declared an $0.08 quarterly dividend and approved a new $500 million share repurchase program.
Net sales were $316.2 million, up 4% reported and 6% organic.
GAAP EPS was $0.14 versus $0.31 a year earlier; adjusted EPS was $0.56 versus $0.48.
GAAP operating income fell 42% to $38.7 million, including $38.9 million in certain litigation charges.
Dividend of $0.08 per share payable May 30, 2025; new $500 million buyback begins May 8, 2025.
On February 26, 2025, an arbitrator ruled in favor of former CEO Charles R. Kummeth in a dispute over 794,400 vested options that the company had treated as expired following an administrative error. The company must pay Kummeth approximately $35,978,000 for the options, plus about $980,000 in interest and about $234,000 in legal fees and costs, which will reduce shareholder value.
Arbitrator's order dated February 26, 2025 found Kummeth would have exercised his options before the August 9, 2024 expiration date.
Payment for the options is approximately $35,978,000, measured by the 30-day average closing price before the Award Agreement expiration date.
Additional amounts are approximately $980,000 in interest and approximately $234,000 in legal fees and costs.
The dispute arose from an administrative error in the stock plan platform, which showed an October 26, 2024 expiration date.
Bio-Techne reported second-quarter fiscal 2025 results with net sales up 9% to $297.0 million and GAAP diluted EPS of $0.22, up from $0.17 a year earlier. Adjusted EPS rose to $0.42 from $0.40, while the adjusted operating margin held flat at 30.1%. For shareholders, quarterly revenue and profit both improved, though six-month GAAP diluted EPS was $0.42 versus $0.49 a year earlier.
Net sales rose 9% to $297.0 million for the quarter ended December 31, 2024.
GAAP diluted EPS was $0.22 versus $0.17; adjusted diluted EPS was $0.42 versus $0.40.
GAAP operating income increased 25% to $47.4 million; adjusted operating margin was flat at 30.1%.
Board appointed Dr. Amy Herr as an independent director effective February 1, 2025; a $0.08 per share quarterly dividend was also declared.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bio-Techne filing is on SEC EDGAR ↗. 8-K briefs of other companies →